Web based Drug Database (1.07 Linux)

ATENOLOL [ORAL]

Names
Common Name	ATENOLOL [ORAL]
Other Name	ATENOLOL [ORAL]
Pharmacological Group	CARDIOSELECTIVE BETA BLOCKERS
Chemical Name	4-(2-Hydroxy-3-isopropylaminopropoxy)phenylacetamide; 2-{p-[2-Hydroxy-3-(isopropylamino)propoxy]phenyl}acetamide
Chemical Group

Attributes

Indications	Contraindications	Prescriber Cautions	Patient Cautions
Toxicity	Side Effects	Liver Disease	Renal Failure
Pregnancy	Lactation	Pharmacological Actions	Diagnostic Procedures
Drugs	Interactions

Indications

Hypertension
Myocardial infarction
Acute myocardial infarction
Angina pectoris
Paroxysmal supraventricular tachycardia
Atrial fibrillation and flutter
Sinus tachycardia
Supraventricular tachycardia
Hypertension complicating pregnancy/childbirth/puerperium
Paediatric use

Contraindications

Heart failure
Chronic obstructive airway disease
Asthma
Pulse rate - bradycardia
Complete atrioventricular block
Partial atrioventricular block
Sick sinus syndrome
Raynaud's syndrome
Chronic obstructive pulmonary disease
Chronic asthmatic bronchitis
Cardiogenic shock
Adverse reaction to betablockers
Adverse reaction to atenolol
Airways obstruction reversible
Beta blocker contraindicated
Betablocker allergy

Prescriber Cautions

Withdraw ATENOLOL [ORAL] gradually over at least a week
Caution in asthma or other obstructive pulmonary disease

Patient Cautions

See information on products containing ATENOLOL [ORAL] for specific advice for patients

Toxicity

- None Listed -

Side Effects

Bradycardia - Common
Cold extremities - Common
Diarrhoea - Common
Fatigue/asthenia - Common
ALT/SGPT level abnormal - Uncommon
AST/SGOT level raised - Uncommon
Gamma GT level abnormal - Uncommon
Insomnia - Uncommon
Allergic purpura - Rare
Blurred Vision - Rare
Bronchospasm - Rare
Cardiac conduction disorders - Rare
Confusion - Rare
Dizziness - Rare
Drug psychoses - Rare
Dry eyes - Rare
Dry mouth - Rare
Gallbladder disorders including Cholestasis - Rare
Hallucinations - Rare
Headache - Rare
Heart failure - Rare
Impotence - Rare
Intermittent claudication - Rare
Mood swings - Rare
Nightmares - Rare
Paraesthesia - Rare
Patches of alopecia - Rare
Postural hypotension - Rare
Psoriasiform rash - Rare
Rash - Rare
Raynaud's phenomenon - Rare
Syncope - Rare
Thrombocytopenia - Rare
Anti-nuclear factor positive - Very Rare
Angioneurotic oedema

Liver Disease

Liver disease may alter the response to drugs in several ways. Prescribing should be kept to a minimum in all patients with severe liver disease, especially if jaundice, ascites, or evidence of encephalopathy present

Renal Failure

Excreted by kidney unchanged
Reduce dose of ATENOLOL [ORAL] in moderate renal failure
Use small starting dose of ATENOLOL [ORAL] in severe renal failure
ATENOLOL [ORAL] - may reduce renal blood flow and reduce renal function in severe renal failure
ATENOLOL [ORAL] - higher serum concentrations after oral administration in severe renal failure

Pregnancy

ATENOLOL [ORAL] may retard intrauterine fetal growth
ATENOLOL [ORAL] causes neonatal bradycardia related to maternal dose
Avoid ATENOLOL [ORAL] in the 1st & 2nd TRIMESTER of pregnancy
Risk of neonatal hypoglycaemia with ATENOLOL [ORAL]

Lactation

Therapeutic doses of ATENOLOL [ORAL] unlikely to affect infant
Monitor infant
ATENOLOL [ORAL] present in breast milk in greater amounts than other beta-blockers
Possible toxicity from ATENOLOL [ORAL] due to beta-blocker effect

Pharmacological Actions

BETA ANTAGONIST action effect
BETA1 ANTAGONIST effect

Diagnostic Procedures

Urine 5-hydroxyindoleacetic acid high
Total bilirubin high
Creatine kinase low
Serum glucose low

Drugs containing ATENOLOL [ORAL]

TENORMIN 100mg tablets
TENORMIN 25mg/5mL syrup
TENORMIN LS 50mg tablets
ATENOLOL 50mg tablets
ATENOLOL 100mg tablets
TENORMIN 25 tablets
ATENOLOL 25mg tablets
ATENOLOL 25mg/5mL syrup
KALTEN capsules
TOTARETIC 50mg/12.5mg tablets
TOTARETIC 100mg/25mg tablets
COMBITENS m/r capsules
TENORET-50 tablets
TENORETIC tablets
CO-TENIDONE 50/12.5mg tablets
CO-TENIDONE 100/25mg tablets
BETA-ADALAT 50/20mg capsules
TENIF 50/20mg capsules
ATENOL+CO-AMILOZ 50/2.5/25mg
ATENOLOL+NIFEDIP 50/20mg m/r
Atenolol 25mg/5ml sf oral soln
Co-tenid 100mg/25mg/5ml soln
Co-tenid 100mg/25mg/5ml susp
Atenolol 10mg/5ml oral soln
Atenolol 10mg/5ml oral susp
Atenolol 12.5mg/5ml oral soln
Atenolol 12.5mg/5ml oral susp
Atenolol 25mg/5ml oral soln
Atenolol 25mg/5ml oral susp
Atenolol 3.125mg/5ml oral soln
Atenolol 3.125mg/5ml oral susp
Atenolol 3mg/5ml oral solution
Atenolol 3mg/5ml oral susp
Atenolol 50mg/5ml oral soln
Atenolol 50mg/5ml oral susp
Atenolol s/f 25mg/5ml 300ml Al

Interacting Ingredients

ACETOHEXAMIDE
Infrequent reports of ATENOLOL [ORAL] increasing the HYPOGLYCAEMIC effect of ACETOHEXAMIDE. Moderate risk. Monitor
ALFUZOSIN HYDROCHLORIDE
Infrequent reports of ATENOLOL [ORAL] increasing the HYPOTENSIVE effect of ALFUZOSIN HYDROCHLORIDE. Potential risk. May need to avoid combination
ALMOTRIPTAN
Infrequent reports of ATENOLOL [ORAL] increasing the VASOCONSTRICTOR effect of ALMOTRIPTAN. Potential risk. Avoid
AMINOPHYLLINE
Infrequent reports of ATENOLOL [ORAL] reducing the BRONCHODILATOR effect of AMINOPHYLLINE. Potential risk. Avoid
AMIODARONE HYDROCHLORIDE
Likely interaction of ATENOLOL [ORAL] increasing the ARRHYTHMOGENIC effect of AMIODARONE HYDROCHLORIDE. Potential risk. May need to avoid combination
AMPICILLIN
Likely interaction of AMPICILLIN reducing the GASTRO-INTESTINAL ABSORPTION of ATENOLOL [ORAL]. Moderate risk. Monitor
BAMBUTEROL HYDROCHLORIDE
Infrequent reports of ATENOLOL [ORAL] reducing the BRONCHODILATOR effect of BAMBUTEROL HYDROCHLORIDE. Potential risk. Avoid
BECLOMETASONE [INHALED]
Infrequent reports of ATENOLOL [ORAL] reducing the BRONCHODILATOR effect of BECLOMETASONE [INHALED]. Potential risk. Avoid
BETAMETHASONE [INHALED]
Infrequent reports of ATENOLOL [ORAL] reducing the BRONCHODILATOR effect of BETAMETHASONE [INHALED]. Potential risk. Avoid
BIPHASIC INSULIN ASPART
Infrequent reports of ATENOLOL [ORAL] increasing the HYPOGLYCAEMIC effect of BIPHASIC INSULIN ASPART. Moderate risk. Monitor
BIPHASIC INSULIN LISPRO
Infrequent reports of ATENOLOL [ORAL] increasing the HYPOGLYCAEMIC effect of BIPHASIC INSULIN LISPRO. Moderate risk. Monitor
BUDESONIDE [INHALED]
Infrequent reports of ATENOLOL [ORAL] reducing the BRONCHODILATOR effect of BUDESONIDE [INHALED]. Potential risk. Avoid
BUFYLLINE
Infrequent reports of ATENOLOL [ORAL] reducing the BRONCHODILATOR effect of BUFYLLINE. Potential risk. Avoid
CARBENOXOLONE
Likely interaction of CARBENOXOLONE reducing the HYPOTENSIVE effect of ATENOLOL [ORAL]. Potential risk. Monitor
CARBENOXOLONE [MOUTH]
Likely interaction of CARBENOXOLONE [MOUTH] reducing the HYPOTENSIVE effect of ATENOLOL [ORAL]. Potential risk. Monitor
CHLORPROMAZINE
Theoretical potential for CHLORPROMAZINE increasing the HYPOTENSIVE effect of ATENOLOL [ORAL]. Potential risk. May need to avoid combination
CHLORPROPAMIDE
Infrequent reports of ATENOLOL [ORAL] increasing the HYPOGLYCAEMIC effect of CHLORPROPAMIDE. Moderate risk. Monitor
CHOLINE THEOPHYLLINATE
Infrequent reports of ATENOLOL [ORAL] reducing the BRONCHODILATOR effect of CHOLINE THEOPHYLLINATE. Potential risk. Avoid
CIMETIDINE
Infrequent reports of CIMETIDINE increasing the NEGATIVE CHRONOTROPIC effect of ATENOLOL [ORAL]. Usually no risk. Usually no action necessary
CLONIDINE
Likely interaction of ATENOLOL [ORAL] increasing the HYPOTENSIVE effect of CLONIDINE. Potential risk. May need to avoid combination
CROMOGLICATE [INHALED]
Infrequent reports of ATENOLOL [ORAL] reducing the BRONCHODILATOR effect of CROMOGLICATE [INHALED]. Potential risk. Avoid
DARBEPOETIN ALFA
Theoretical potential for DARBEPOETIN ALFA reducing the HYPOTENSIVE effect of ATENOLOL [ORAL]. Moderate risk. Monitor
DEMECARIUM BROMIDE
Infrequent reports of DEMECARIUM BROMIDE increasing the NEGATIVE CHRONOTROPIC effect of ATENOLOL [ORAL]. Moderate risk. Monitor
DEXIBUPROFEN
Infrequent reports of DEXIBUPROFEN reducing the HYPOTENSIVE effect of ATENOLOL [ORAL]. Moderate risk. Monitor
DIGITOXIN
Infrequent reports of ATENOLOL [ORAL] increasing the NEGATIVE CHRONOTROPIC effect of DIGITOXIN. Moderate risk. May need to avoid combination
DIGOXIN
Infrequent reports of ATENOLOL [ORAL] increasing the NEGATIVE CHRONOTROPIC effect of DIGOXIN. Moderate risk. May need to avoid combination
DIHYDROERGOTAMINE MESILATE
Infrequent reports of DIHYDROERGOTAMINE MESILATE increasing the VASOCONSTRICTOR effect of ATENOLOL [ORAL]. Moderate risk. Monitor
DILTIAZEM HYDROCHLORIDE
Infrequent reports of DILTIAZEM HYDROCHLORIDE increasing the NEGATIVE INOTROPIC effect of ATENOLOL [ORAL]. Moderate risk. Monitor
DIPROPHYLLINE
Infrequent reports of ATENOLOL [ORAL] reducing the BRONCHODILATOR effect of DIPROPHYLLINE. Potential risk. Avoid
DISOPYRAMIDE
Infrequent reports of ATENOLOL [ORAL] increasing the NEGATIVE CHRONOTROPIC effect of DISOPYRAMIDE. Moderate risk. May need to avoid combination
DISTIGMINE
Infrequent reports of DISTIGMINE increasing the NEGATIVE CHRONOTROPIC effect of ATENOLOL [ORAL]. Moderate risk. Monitor
ECOTHIOPATE IODIDE
Infrequent reports of ECOTHIOPATE IODIDE increasing the NEGATIVE CHRONOTROPIC effect of ATENOLOL [ORAL]. Moderate risk. Monitor
EDROPHONIUM
Infrequent reports of EDROPHONIUM increasing the NEGATIVE CHRONOTROPIC effect of ATENOLOL [ORAL]. Moderate risk. Monitor
ELETRIPTAN
Infrequent reports of ATENOLOL [ORAL] increasing the VASOCONSTRICTOR effect of ELETRIPTAN. Potential risk. Avoid
EPHEDRINE HYDROCHLORIDE
Infrequent reports of ATENOLOL [ORAL] reducing the BRONCHODILATOR effect of EPHEDRINE HYDROCHLORIDE. Potential risk. Avoid
EPOETIN ALFA
Theoretical potential for EPOETIN ALFA reducing the HYPOTENSIVE effect of ATENOLOL [ORAL]. Moderate risk. Monitor
EPOETIN BETA
Theoretical potential for EPOETIN BETA reducing the HYPOTENSIVE effect of ATENOLOL [ORAL]. Moderate risk. Monitor
EPOETIN THETA
Theoretical potential for EPOETIN THETA reducing the HYPOTENSIVE effect of ATENOLOL [ORAL]. Moderate risk. Monitor
EPOETIN ZETA
Theoretical potential for EPOETIN ZETA reducing the HYPOTENSIVE effect of ATENOLOL [ORAL]. Moderate risk. Monitor
ERGOTAMINE TARTRATE
Infrequent reports of ERGOTAMINE TARTRATE increasing the VASOCONSTRICTOR effect of ATENOLOL [ORAL]. Moderate risk. Monitor
FELODIPINE
Infrequent reports of FELODIPINE increasing the NEGATIVE INOTROPIC effect of ATENOLOL [ORAL]. Moderate risk. Monitor
FENOTEROL HYDROBROMIDE
Infrequent reports of ATENOLOL [ORAL] reducing the BRONCHODILATOR effect of FENOTEROL HYDROBROMIDE. Potential risk. Avoid
FLECAINIDE ACETATE
Infrequent reports of ATENOLOL [ORAL] increasing the BETA ANTAGONIST effect of FLECAINIDE ACETATE. Moderate risk. Monitor
FLUTICASONE [INHALED]
Infrequent reports of ATENOLOL [ORAL] reducing the BRONCHODILATOR effect of FLUTICASONE [INHALED]. Potential risk. Avoid
FORMOTEROL
Infrequent reports of ATENOLOL [ORAL] reducing the BRONCHODILATOR effect of FORMOTEROL. Potential risk. Avoid
FROVATRIPTAN
Infrequent reports of ATENOLOL [ORAL] increasing the VASOCONSTRICTOR effect of FROVATRIPTAN. Potential risk. Avoid
GALANTAMINE
Infrequent reports of GALANTAMINE increasing the NEGATIVE CHRONOTROPIC effect of ATENOLOL [ORAL]. Moderate risk. Monitor
GLIBENCLAMIDE
Infrequent reports of ATENOLOL [ORAL] increasing the HYPOGLYCAEMIC effect of GLIBENCLAMIDE. Moderate risk. Monitor
GLIBORNURIDE
Infrequent reports of ATENOLOL [ORAL] increasing the HYPOGLYCAEMIC effect of GLIBORNURIDE. Moderate risk. Monitor
GLICLAZIDE
Infrequent reports of ATENOLOL [ORAL] increasing the HYPOGLYCAEMIC effect of GLICLAZIDE. Moderate risk. Monitor
GLIMEPIRIDE
Infrequent reports of ATENOLOL [ORAL] increasing the HYPOGLYCAEMIC effect of GLIMEPIRIDE. Moderate risk. Monitor
GLIPIZIDE
Infrequent reports of ATENOLOL [ORAL] increasing the HYPOGLYCAEMIC effect of GLIPIZIDE. Moderate risk. Monitor
GLIQUIDONE
Infrequent reports of ATENOLOL [ORAL] increasing the HYPOGLYCAEMIC effect of GLIQUIDONE. Moderate risk. Monitor
GLYMIDINE
Infrequent reports of ATENOLOL [ORAL] increasing the HYPOGLYCAEMIC effect of GLYMIDINE. Moderate risk. Monitor
HUMAN INSULIN [INHALED]
Infrequent reports of ATENOLOL [ORAL] increasing the HYPOGLYCAEMIC effect of HUMAN INSULIN [INHALED]. Moderate risk. Monitor
IBUPROFEN
Infrequent reports of IBUPROFEN reducing the HYPOTENSIVE effect of ATENOLOL [ORAL]. Moderate risk. Monitor
IBUPROFEN LYSINE
Infrequent reports of IBUPROFEN LYSINE reducing the HYPOTENSIVE effect of ATENOLOL [ORAL]. Moderate risk. Monitor
INDACATEROL
Infrequent reports of ATENOLOL [ORAL] reducing the BRONCHODILATOR effect of INDACATEROL. Potential risk. Avoid
INDOMETACIN
Likely interaction of INDOMETACIN reducing the HYPOTENSIVE effect of ATENOLOL [ORAL]. Potential risk. Monitor
INDOMETACIN [RECTUM]
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of ATENOLOL [ORAL]. Potential risk. Monitor
INSULIN ASPART
Infrequent reports of ATENOLOL [ORAL] increasing the HYPOGLYCAEMIC effect of INSULIN ASPART. Moderate risk. Monitor
INSULIN DETEMIR
Infrequent reports of ATENOLOL [ORAL] increasing the HYPOGLYCAEMIC effect of INSULIN DETEMIR. Moderate risk. Monitor
INSULIN GLARGINE
Infrequent reports of ATENOLOL [ORAL] increasing the HYPOGLYCAEMIC effect of INSULIN GLARGINE. Moderate risk. Monitor
INSULIN GLULISINE
Infrequent reports of ATENOLOL [ORAL] increasing the HYPOGLYCAEMIC effect of INSULIN GLULISINE. Moderate risk. Monitor
INSULIN LISPRO
Infrequent reports of ATENOLOL [ORAL] increasing the HYPOGLYCAEMIC effect of INSULIN LISPRO. Moderate risk. Monitor
ISOETARINE HYDROCHLORIDE
Infrequent reports of ATENOLOL [ORAL] reducing the BRONCHODILATOR effect of ISOETARINE HYDROCHLORIDE. Potential risk. Avoid
ISOPRENALINE HYDROCHLORIDE
Infrequent reports of ATENOLOL [ORAL] reducing the BRONCHODILATOR effect of ISOPRENALINE HYDROCHLORIDE. Potential risk. Avoid
ISOPRENALINE SULPHATE
Infrequent reports of ATENOLOL [ORAL] reducing the BRONCHODILATOR effect of ISOPRENALINE SULPHATE. Potential risk. Avoid
ISRADIPINE
Infrequent reports of ISRADIPINE increasing the NEGATIVE INOTROPIC effect of ATENOLOL [ORAL]. Moderate risk. Monitor
KETOTIFEN
Infrequent reports of ATENOLOL [ORAL] reducing the BRONCHODILATOR effect of KETOTIFEN. Potential risk. Avoid
LACIDIPINE
Infrequent reports of LACIDIPINE increasing the NEGATIVE INOTROPIC effect of ATENOLOL [ORAL]. Moderate risk. Monitor
LERCANIDIPINE
Infrequent reports of LERCANIDIPINE increasing the NEGATIVE INOTROPIC effect of ATENOLOL [ORAL]. Moderate risk. Monitor
LEVODOPA
Theoretical potential for LEVODOPA increasing the HYPOTENSIVE effect of ATENOLOL [ORAL]. Moderate risk. May need to avoid combination
LEVOMEPROMAZINE
Theoretical potential for LEVOMEPROMAZINE increasing the HYPOTENSIVE effect of ATENOLOL [ORAL]. Potential risk. May need to avoid combination
MEFLOQUINE HYDROCHLORIDE
Likely interaction of ATENOLOL [ORAL] increasing the ARRHYTHMOGENIC effect of MEFLOQUINE HYDROCHLORIDE. Moderate risk. May need to avoid combination
METFORMIN HYDROCHLORIDE
Infrequent reports of ATENOLOL [ORAL] increasing the HYPOGLYCAEMIC effect of METFORMIN HYDROCHLORIDE. Moderate risk. Monitor
METHOXY POLYETHYLENE GLYCOL EPOETIN BETA
Theoretical potential for METHOXY POLYETHYLENE GLYCOL EPOETIN BETA reducing the HYPOTENSIVE effect of ATENOLOL [ORAL]. Moderate risk. Monitor
METHYSERGIDE
Infrequent reports of METHYSERGIDE increasing the VASOCONSTRICTOR effect of ATENOLOL [ORAL]. Moderate risk. Monitor
MONTELUKAST
Infrequent reports of ATENOLOL [ORAL] reducing the BRONCHODILATOR effect of MONTELUKAST. Potential risk. Avoid
MOXISYLYTE
Likely interaction of ATENOLOL [ORAL] increasing the HYPOTENSIVE effect of MOXISYLYTE. Potential risk. May need to avoid combination
MOXONIDINE
Theoretical potential for ATENOLOL [ORAL] reducing the HYPOTENSIVE effect of MOXONIDINE. Moderate risk. May need to avoid combination
NAPROXEN
Infrequent reports of NAPROXEN reducing the HYPOTENSIVE effect of ATENOLOL [ORAL]. Moderate risk. Monitor
NAPROXEN SODIUM
Infrequent reports of NAPROXEN SODIUM reducing the HYPOTENSIVE effect of ATENOLOL [ORAL]. Moderate risk. Monitor
NAPROXEN [RECTUM]
Infrequent reports of NAPROXEN [RECTUM] reducing the HYPOTENSIVE effect of ATENOLOL [ORAL]. Moderate risk. Monitor
NEDOCROMIL SODIUM
Infrequent reports of ATENOLOL [ORAL] reducing the BRONCHODILATOR effect of NEDOCROMIL SODIUM. Potential risk. Avoid
NEOSTIGMINE
Infrequent reports of NEOSTIGMINE increasing the NEGATIVE CHRONOTROPIC effect of ATENOLOL [ORAL]. Moderate risk. Monitor
NEOSTIGMINE [EYE]
Infrequent reports of NEOSTIGMINE [EYE] increasing the NEGATIVE CHRONOTROPIC effect of ATENOLOL [ORAL]. Moderate risk. Monitor
NICARDIPINE HYDROCHLORIDE
Infrequent reports of NICARDIPINE HYDROCHLORIDE increasing the NEGATIVE INOTROPIC effect of ATENOLOL [ORAL]. Moderate risk. Monitor
NIFEDIPINE
Infrequent reports of NIFEDIPINE increasing the NEGATIVE INOTROPIC effect of ATENOLOL [ORAL]. Moderate risk. Monitor
NIMODIPINE
Infrequent reports of NIMODIPINE increasing the NEGATIVE INOTROPIC effect of ATENOLOL [ORAL]. Moderate risk. Monitor
NISOLDIPINE
Infrequent reports of NISOLDIPINE increasing the NEGATIVE INOTROPIC effect of ATENOLOL [ORAL]. Moderate risk. Monitor
NIZATIDINE
Theoretical potential for NIZATIDINE increasing the NEGATIVE CHRONOTROPIC effect of ATENOLOL [ORAL]. Usually no risk. Usually no action necessary
ORCIPRENALINE
Infrequent reports of ATENOLOL [ORAL] reducing the BRONCHODILATOR effect of ORCIPRENALINE. Potential risk. Avoid
ORCIPRENALINE [INHALED]
Infrequent reports of ATENOLOL [ORAL] reducing the BRONCHODILATOR effect of ORCIPRENALINE [INHALED]. Potential risk. Avoid
PHENYLPROPANOLAMINE HYDROCHLORIDE
Likely interaction of PHENYLPROPANOLAMINE HYDROCHLORIDE reducing the HYPOTENSIVE effect of ATENOLOL [ORAL]. Usually no risk. Usually no action necessary
PHYSOSTIGMINE SULPHATE
Infrequent reports of PHYSOSTIGMINE SULPHATE increasing the NEGATIVE CHRONOTROPIC effect of ATENOLOL [ORAL]. Moderate risk. Monitor
PIRBUTEROL
Infrequent reports of ATENOLOL [ORAL] reducing the BRONCHODILATOR effect of PIRBUTEROL. Potential risk. Avoid
PIROXICAM
Likely interaction of PIROXICAM reducing the HYPOTENSIVE effect of ATENOLOL [ORAL]. Moderate risk. Monitor
PIROXICAM [RECTUM]
Likely interaction of PIROXICAM [RECTUM] reducing the HYPOTENSIVE effect of ATENOLOL [ORAL]. Moderate risk. Monitor
PIROXICAM-BETADEX
Likely interaction of PIROXICAM-BETADEX reducing the HYPOTENSIVE effect of ATENOLOL [ORAL]. Moderate risk. Monitor
PRAZOSIN HYDROCHLORIDE
Infrequent reports of ATENOLOL [ORAL] increasing the HYPOTENSIVE effect of PRAZOSIN HYDROCHLORIDE. Potential risk. May need to avoid combination
PRENYLAMINE
Likely interaction of ATENOLOL [ORAL] increasing the NEGATIVE INOTROPIC effect of PRENYLAMINE. High risk. Monitor
PYRIDOSTIGMINE BROMIDE
Infrequent reports of PYRIDOSTIGMINE BROMIDE increasing the NEGATIVE CHRONOTROPIC effect of ATENOLOL [ORAL]. Moderate risk. Monitor
QUINIDINE
Infrequent reports of ATENOLOL [ORAL] increasing the NEGATIVE CHRONOTROPIC effect of QUINIDINE. Moderate risk. May need to avoid combination
REPROTEROL HYDROCHLORIDE
Infrequent reports of ATENOLOL [ORAL] reducing the BRONCHODILATOR effect of REPROTEROL HYDROCHLORIDE. Potential risk. Avoid
RIMITEROL HYDROBROMIDE
Infrequent reports of ATENOLOL [ORAL] reducing the BRONCHODILATOR effect of RIMITEROL HYDROBROMIDE. Potential risk. Avoid
RITODRINE HYDROCHLORIDE
Infrequent reports of ATENOLOL [ORAL] reducing the BRONCHODILATOR effect of RITODRINE HYDROCHLORIDE. Potential risk. Avoid
RIVASTIGMINE
Infrequent reports of RIVASTIGMINE increasing the NEGATIVE CHRONOTROPIC effect of ATENOLOL [ORAL]. Moderate risk. Monitor
SALBUTAMOL
Infrequent reports of ATENOLOL [ORAL] reducing the BRONCHODILATOR effect of SALBUTAMOL. Potential risk. Avoid
SALBUTAMOL [INHALED]
Infrequent reports of ATENOLOL [ORAL] reducing the BRONCHODILATOR effect of SALBUTAMOL [INHALED]. Potential risk. Avoid
SALMETEROL XINAFOATE
Infrequent reports of ATENOLOL [ORAL] reducing the BRONCHODILATOR effect of SALMETEROL XINAFOATE. Potential risk. Avoid
SUMATRIPTAN SUCCINATE
Infrequent reports of ATENOLOL [ORAL] increasing the VASOCONSTRICTOR effect of SUMATRIPTAN SUCCINATE. Potential risk. Avoid
TERAZOSIN HYDROCHLORIDE
Infrequent reports of ATENOLOL [ORAL] increasing the HYPOTENSIVE effect of TERAZOSIN HYDROCHLORIDE. Potential risk. May need to avoid combination
TERBUTALINE
Infrequent reports of ATENOLOL [ORAL] reducing the BRONCHODILATOR effect of TERBUTALINE. Potential risk. Avoid
TERBUTALINE [INHALED]
Infrequent reports of ATENOLOL [ORAL] reducing the BRONCHODILATOR effect of TERBUTALINE [INHALED]. Potential risk. Avoid
THEOPHYLLINE
Infrequent reports of ATENOLOL [ORAL] reducing the BRONCHODILATOR effect of THEOPHYLLINE. Potential risk. Avoid
TOLAZAMIDE
Infrequent reports of ATENOLOL [ORAL] increasing the HYPOGLYCAEMIC effect of TOLAZAMIDE. Moderate risk. Monitor
TOLBUTAMIDE
Infrequent reports of ATENOLOL [ORAL] increasing the HYPOGLYCAEMIC effect of TOLBUTAMIDE. Moderate risk. Monitor
TULOBUTEROL HYDROCHLORIDE
Infrequent reports of ATENOLOL [ORAL] reducing the BRONCHODILATOR effect of TULOBUTEROL HYDROCHLORIDE. Potential risk. Avoid
VERAPAMIL HYDROCHLORIDE
Infrequent reports of VERAPAMIL HYDROCHLORIDE increasing the NEGATIVE INOTROPIC effect of ATENOLOL [ORAL]. Moderate risk. Monitor
ZAFIRLUKAST
Infrequent reports of ATENOLOL [ORAL] reducing the BRONCHODILATOR effect of ZAFIRLUKAST. Potential risk. Avoid